A Complement-Optimized EGFR Antibody Improves Cytotoxic Functions of Polymorphonuclear Cells against Tumor Cells.

@article{Derer2015ACE,
  title={A Complement-Optimized EGFR Antibody Improves Cytotoxic Functions of Polymorphonuclear Cells against Tumor Cells.},
  author={Stefanie Derer and Michael Cossham and Thies R{\"o}sner and Christian Johannes Kellner and Frank J Beurskens and Ralf Schwanbeck and Stefan Lohse and Christian Sina and Matthias Peipp and Thomas Valerius},
  journal={Journal of immunology},
  year={2015},
  volume={195 10},
  pages={5077-87}
}
Complement-dependent cytotoxicity (CDC) has been suggested to be an important mechanism of action of tumor-targeting Abs. However, single unmodified epidermal growth factor receptor (EGFR)-targeting IgG1 Abs fail to trigger efficient CDC. For the current study, we generated a CDC-optimized variant of the EGFR Ab matuzumab (H425 wt) by introducing amino acid substitutions K326A/E333A (H425 mt). This Ab was then used to elucidate the impact of complement activation on the capacity of effector… CONTINUE READING
Recent Discussions
This paper has been referenced on Twitter 1 time over the past 90 days. VIEW TWEETS

References

Publications referenced by this paper.
Showing 1-10 of 57 references

plement in antibody - based tumor therapy

  • T. Valerius
  • Crit . Rev . Immunol .
  • 2014

Similar Papers

Loading similar papers…